2-Anilino-4-amino-pyrimidon-(4) | 46338-72-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Anilino-4-amino-pyrimidon-(4)
• 英文别名: 2-Anilino-4-aminopyrimidin；N²-phenyl-pyrimidine-2,4-diamine；N²-phenyl-pyrimidine-2,4-diyldiamine；N²-Phenyl-pyrimidin-2,4-diyldiamin；N2-Phenyl-2,4-pyrimidinediamine；2-N-phenylpyrimidine-2,4-diamine
• CAS: 46338-72-1
• 化学式: C₁₀H₁₀N₄
• 分子量: 186.216
• InChiKey: UIPJIUQDINJHJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氨基-2-氯嘧啶 、 苯胺 生成 2-Anilino-4-amino-pyrimidon-(4)
  参考文献：
  名称：

  Arylaminoheterocycles. II. Arylaminopyrimidines

  摘要：

  DOI：

  10.1021/ja01235a023

文献信息

• 2,4-pyrimidinediamine compounds and their uses
  申请人：Rigel Pharmaceuticals, Inc

  公开号：US10314840B2

  公开（公告）日：2019-06-11

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了可抑制导致化学介质释放的 IgE 和/或 IgG 受体信号级联的 2,4-嘧啶二胺化合物、合成该化合物的中间体和方法，以及在各种情况下使用该化合物的方法，包括治疗和预防以通过脱颗粒释放化学介质为特征、由脱颗粒释放化学介质引起或与脱颗粒释放化学介质相关的疾病，以及通过激活 IgE 和/或 IgG 受体信号级联而影响的其他过程。
• Solid Phase Synthesis of Diamino-Substituted Pyrimidines
  作者：Caterina Barillari、Daniela Barlocco、Luca F. Raveglia

  DOI：10.1002/1099-0690(200112)2001:24<4737::aid-ejoc4737>3.0.co;2-1

  日期：2001.12

  2,4- and 4,6-Diamino-substituted pyrimidines are known for their biological activity in many therapeutic areas. A novel solid-phase synthesis of this class of compounds by nucleophilic aromatic substitution has been set up and the reactivity of differently substituted solid-supported pyrimidines with properly selected amines has been studied, Using this methodology a small library of diamino-substituted pyrimidines has been prepared.
• 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170081290A1

  公开（公告）日：2017-03-23

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170151239A1

  公开（公告）日：2017-06-01

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20210198277A1

  公开（公告）日：2021-07-01

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.